S.Korea's Biorchestra signs tech transfer deal for drug delivery system

The company signed an $860 mn joint research and option contract with an undisclosed global biotech firm

S.Korea's Biorchestra signs tech transfer deal for drug delivery system
Jeong Min Nam 1
2023-03-28 15:44:24 peux@hankyung.com
Bio & Pharma

Biorchestra Co., a South Korean company specializing in RNA-based therapeutics, announced on Tuesday that it has entered into a joint research and option contract with a global biotech company to transfer its brain-targeting polymer-based drug delivery technology. The identity of the contracting party was not disclosed according to the agreement.

The contract amount is estimated at $861 million (1.1 trillion won).

Under the terms of the agreement, Biorchestra will provide its drug delivery technology, BDDS, and the partner company plans to apply this technology to nucleic acid drug candidates to develop new drugs that can treat various neurodegenerative brain diseases.

"We are excited to have entered into a partnership with a global pharmaceutical company.  We will do our best with our partner to develop new drugs that can make a significant difference in the lives of patients," said Branden Ryu, CEO of Biorchestra.

Write to Jeong Min Nam at peux@hankyung.com
#Biorchestra #RNA-based therapeutics #drug delivery system #BDDS #nucleic acid drug candidates #neurodegenerative brain diseases #korea biorchestra rna

GC Biopharma to develop mRNA flu vaccine with Canadian pharma

GC Biopharma to develop mRNA flu vaccine with Canadian pharma

South Korea's GC Biopharma Co. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The drug maker said it has exercised an option contract with Acuitas Therapeutics, a Canadian pharma that specializes in lipid nano particle (LNP) deliver

Moderna to stay ahead in mRNA technology: CSO Melissa Moore

Moderna to stay ahead in mRNA technology: CSO Melissa Moore

Melissa Moore, Moderna's chief scientific officer CAMBRIDGE, MA – The COVID-19 coronavirus disease has been a curse for many people and companies around the world over the past couple of years. The pandemic, however, had a silver lining for biotechnology companies such as Moderna Inc.The

Korean pharma joins global race in RNA therapeutics development

Korean pharma joins global race in RNA therapeutics development

COVID-19 PCR test based on Ribonucleic acid (RNA) The field of ribonucleic acid (RNA) therapeutics, once considered an unexplored area, is now the most coveted sector in the global biotech industry.RNA therapeutics are a new class of medications based on RNA. There has been research on its clin
(* comment hide *}